Pier-Luc Clermont

Dr. Pier-Luc Clermont


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Epigenomics
Verified
Journal Article
Open access
NKNing Kang
Ning Kang
MEMark Eccleston
Mark Eccleston
PCPier-Luc Clermont
Pier-Luc Clermont
MLMaryam Latarani
Maryam Latarani
DMDavid Male
David Male
FCFrancesco Crea
Francesco Crea
Immunotherapies are revolutionizing the clinical management of a wide range of cancers. However, intrinsic or acquired unresponsiveness to immunotherapies does occur due to the dynamic cancer immun...

6 September 2017 in Epigenomics
Verified
Journal Article
Closed access
PCPier-Luc Clermont
Pier-Luc Clermont
LFLorenzo Fornaro
Lorenzo Fornaro
FCFrancesco Crea
Francesco Crea
Aim: Polycomb Group complexes are epigenetic repressors that silence tumor suppressive genes. Studies demonstrated that pharmacologic inhibition of Polycomb Group complexes with 3-deazaneplanocin A (DZNeP) induces cancer cell death by re-expressing silenced genes. Here we evaluate the prognostic significance of DZNeP target genes in gastric and breast cancer. Patients & methods/materials: The prognostic impact of a DZNeP-regulated gene signature was investigated using the KM Plotter and cBio Portal resources containing microarray data from tumor tissue. Results: We report that elevated expression of DZNeP targets is associated with poor clinical outcome in gastric and breast cancer. In gastric cancer, elevated expression of DZNeP signature is inversely correlated with decreased overall survival. In breast cancer, DZNeP signature predicted poor prognosis in HER2+ tumors but not in HER2- neoplasms. Conclusion: These findings demonstrate that DZNeP target genes are not predictive of better but rather of poor...

1 January 2023 in Epigenomics
Verified
Journal Article
Closed access
PCPier-Luc Clermont
Pier-Luc Clermont
Despite recent advances, prostate cancer (PCa) remains a leading cause of cancer morbidity and mortality. Clinically, PCa screening methods display low sensitivity and specificity, leading to subop...

Verified
Journal Article
Open access
PDF file
PJPallavi Jain
Pallavi Jain
PCPier-Luc Clermont
Pier-Luc Clermont
FDFrancis Desmeules
Francis Desmeules
AZAmina Zoubeidi
Amina Zoubeidi
BNBertrand Neveu
Bertrand Neveu
FPFrederic Pouliot
Frederic Pouliot
Localized prostate cancer (PCa) is often curable, whereas metastatic disease treated by castration inevitably progresses toward castration-resistant PCa (CRPC). Most CRPC treatments target androgen receptor (AR) signaling. However, not all CRPC cells rely on AR activity for survival and proliferation. With advances in immunotherapy and fluid biopsies for cancer management, expression systems specific for both AR-positive and -negative PCa are required for virus-based vaccines and cell imaging. To target both AR-responsive and non-responsive cells, we developed a three-step transcriptional amplification (3STA) system based on the progression elevated gene-3 (PEG3) promoter named PEG3AP1-3STA. Notably, we report on different genetic modifications that significantly improved PEG3 promoter’s strength in PCa cells. Adenoviruses incorporating PEG3 promoter with and without transcriptional amplification systems were generated. The potential of PEG3AP1-3STA to target PCa cells was then evaluated in vitro and in vivo in androgen-responsive and non-responsive PCa cell lines. PEG3AP1-3STA was shown to be active in all PCa cell lines and not regulated by androgens, and its activity was amplified 97-fold compared to that of a non-amplified promoter. The PEG3AP1-3STA system can thus be used to target advanced AR+ and AR− cells for imaging or immunovirotherapy in advanced PCa.